Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Istaroxime

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock
    Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971647/0/en/Windtree-Therapeutics-Initiates-SEISMiC-C-Study-of-Istaroxime-in-SCAI-Stage-C-Cardiogenic-Shock-for-Planned-Completion-of-Phase-2b-and-Transition-to-Phase-3.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Windtree Announces Publication Of Istaroxime Phase 2b Design
    Windtree Announces Publication Of Istaroxime Phase 2b Design

    09 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//en/news-release/2024/10/09/2960460/0/en/Windtree-Announces-Publication-of-Positive-Istaroxime-Phase-2b-Study-Trial-Design.html

    GLOBENEWSWIRE
    09 Oct 2024
    Share Share
    Windtree Reports Ph 2b Results For Istaroxime In Heart Failure
    Windtree Reports Ph 2b Results For Istaroxime In Heart Failure

    30 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/09/30/2955170/0/en/Windtree-Announces-Positive-Phase-2b-Topline-Clinical-Results-with-Istaroxime-Significantly-Improving-Cardiac-Function-and-Blood-Pressure-in-Heart-Failure-Patients-in-Early-Cardiog.html

    GLOBENEWSWIRE
    30 Sep 2024
    Share Share
    Windtree’s shock med raises blood pressure in latest phase 2 win
    Windtree’s shock med raises blood pressure in latest phase 2 win

    26 Sep 2024

    // BIOSPACE

    https://www.biospace.com/press-releases/windtree-announces-positive-topline-results-from-its-phase-2b-seismic-extension-study-of-istaroxime-in-early-cardiogenic-shock

    BIOSPACE
    26 Sep 2024
    Share Share
    Windtree Completes Enrollment For Istaroxime Study
    Windtree Completes Enrollment For Istaroxime Study

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940479/0/en/Windtree-Completes-Enrollment-of-Phase-2b-Study-of-Istaroxime-in-Early-Cardiogenic-Shock.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Windtree Therapeutics Announces License Agreement with Lee™s Pharmaceuticals
    Windtree Therapeutics Announces License Agreement with Lee™s Pharmaceuticals

    17 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/17/2810651/0/en/Windtree-Therapeutics-Announces-License-Agreement-with-Lee-s-Pharmaceuticals-to-Develop-and-Commercialize-Istaroxime-Dual-Mechanism-SERCA2a-Activators-and-Rostafuroxin-for-Greater-.html

    GLOBENEWSWIRE
    17 Jan 2024
    Share Share